Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FluMist Price Likely To Be Cut To $20-$25 Per Dose, MedImmune Says

Executive Summary

MedImmune is considering reducing the price for the intranasal flu vaccine FluMist to $20-$25 per dose for the 2004-2005 season, CEO David Mott indicated during a first quarter conference call April 21

You may also be interested in...



MedImmune FluMist price halved

MedImmune is cutting the price of the intranasal influenza vaccine FluMist to $23.50 per dose from the $46 price tag used during the 2003-2004 season. The company previously indicated that a price reduction for FluMist was under consideration following weak sales of the vaccine in its first year on the market (1"The Pink Sheet" April 26, 2004, p. 43). FluMist posted sales of $77 mil. during the 2003-2004 flu season...

MedImmune FluMist price halved

MedImmune is cutting the price of the intranasal influenza vaccine FluMist to $23.50 per dose from the $46 price tag used during the 2003-2004 season. The company previously indicated that a price reduction for FluMist was under consideration following weak sales of the vaccine in its first year on the market (1"The Pink Sheet" April 26, 2004, p. 43). FluMist posted sales of $77 mil. during the 2003-2004 flu season...

MedImmune Gets Back FluMist: Physicians Will Be Focus Post-Wyeth

MedImmune is getting "back to basics" on FluMist promotional efforts with a focus on physician education now that the company has regained sole rights to the intranasal flu vaccine from Wyeth

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel